Related Experiment Video

Updated: Aug 29, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Oncolytic herpes viruses as a potential mechanism for cancer therapy

Emil Lou1

  • 1Department of Microbiology and Immunology, SUNY Upstate Medical University, College of Medicine, Syracuse, NY 13210, USA. loue@mail.upstate.edu

Acta Oncologica (Stockholm, Sweden)
|December 24, 2003
PubMed

Insights

Oncolytic viruses, like herpes simplex virus type-1 (HSV-1), show promise for cancer treatment. Advances in molecular technology allow HSV-1 to be safely engineered for targeted tumor cell destruction, offering a new therapeutic avenue.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Oncolytic viruses have been explored for cancer therapy for decades due to their tumor-lysing capabilities.
  • Recent advancements in molecular technologies have enabled the safe manipulation of viruses for human cancer treatment.
  • Conditionally replication-competent viruses and suicide gene therapy represent revived strategies to complement existing cancer therapies.

Purpose of the Study:

  • To review the progress and potential of oncolytic viruses, specifically herpes simplex virus type-1 (HSV-1), in human cancer treatment.
  • To highlight the genetic and molecular advancements that facilitate the safe application of oncolytic virotherapy.
  • To explore the suitability of HSV-1 as a candidate for oncolytic virotherapy.

Main Methods:

  • Review of scientific literature on oncolytic viruses and their application in cancer therapy.
  • Analysis of the properties of herpes simplex virus type-1 (HSV-1) relevant to oncolytic virotherapy.
  • Exploration of molecular engineering strategies for enhancing viral selectivity and safety.

Main Results:

  • Herpes simplex virus type-1 (HSV-1) possesses inherent cytotoxicity and a large genome, making it a strong candidate for oncolytic virotherapy.
  • HSV-1's ability to efficiently infect cells and its inherent viral-specific thymidine kinase gene enhance its therapeutic potential.
  • Engineered HSV-1 can be made selective for tumor microenvironments, increasing safety and efficacy.

Conclusions:

  • Oncolytic virotherapy, particularly using engineered HSV-1, holds significant potential for treating human cancers.
  • Molecular manipulation has advanced the safety and efficacy of oncolytic viruses for clinical application.
  • Further research and development of HSV-1-based therapies could lead to novel cancer treatment strategies.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...